Jangard Simon, Jayaram-Lindström Nitya, Isacsson Nils Hentati, Matheson Granville James, Plavén-Sigray Pontus, Franck Johan, Borg Jacqueline, Farde Lars, Cervenka Simon
Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden.
Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Addiction. 2023 Jun;118(6):1053-1061. doi: 10.1111/add.16144. Epub 2023 Feb 15.
Whereas striatal dopamine D2 receptor (D2R) availability has shown to be altered in individuals with alcohol use disorder (AUD) and in healthy individuals with a family history of AUD, the role of D2R in the development of AUD is unknown. In this positron emission tomography (PET) study, we measured whether D2R availability is associated with subsequent alcohol use and alcohol-related factors, at a follow-up 8 to 16 years post-PET scan, in social drinkers.
Longitudinal study investigating the association between PET data and later self-report measures in healthy individuals.
Academic research imaging centre in Stockholm, Sweden.
There were 71 individuals (68 of whom had evaluable PET data, 5 females, 42.0 years mean age) from a series of previous PET studies.
One PET examination with the D2R antagonist radioligand [ C]raclopride at baseline and self-report measures assessing alcohol use, drug use, impulsivity, reward sensitivity and family history of alcohol or substance use disorder at follow-up.
We found no evidence for an association between D2R availability and later alcohol use (B = -0.019, B 95% CI = -0.043 to -0.006, P = 0.147) nor for the majority of the alcohol-related factors (B 95% CI = -0.034 to 0.004, P = 0.273-0.288). A negative association with a small effect size was found between D2R availability and later impulsivity (B = -0.017, B 95% CI = -0.034 to -0.001, P = 0.046).
Low striatal dopamine D2 receptor availability may not be a strong predictor in the development of alcohol use disorder.
虽然已经表明，酒精使用障碍（AUD）患者以及有AUD家族史的健康个体的纹状体多巴胺D2受体（D2R）可用性会发生改变，但D2R在AUD发展中的作用尚不清楚。在这项正电子发射断层扫描（PET）研究中，我们测量了在PET扫描后8至16年的随访中，社交饮酒者的D2R可用性是否与随后的酒精使用及酒精相关因素有关。
纵向研究，调查健康个体中PET数据与后期自我报告测量之间的关联。
瑞典斯德哥尔摩的学术研究成像中心。
来自一系列先前PET研究的71名个体（其中68名有可评估的PET数据，5名女性，平均年龄42.0岁）。
在基线时进行一次使用D2R拮抗剂放射性配体[C]雷氯必利的PET检查，并在随访时进行自我报告测量，评估酒精使用、药物使用、冲动性、奖励敏感性以及酒精或物质使用障碍的家族史。
我们没有发现证据表明D2R可用性与后期酒精使用之间存在关联（B = -0.019，B 95%置信区间 = -0.043至-0.006，P = 0.147），也没有发现与大多数酒精相关因素存在关联（B 95%置信区间 = -0.034至0.004，P = 0.273 - 0.288）。发现D2R可用性与后期冲动性之间存在负相关，效应量较小（B = -0.017，B 95%置信区间 = -0.034至-0.001，P = 0.046）。
纹状体多巴胺D2受体可用性较低可能不是酒精使用障碍发展的有力预测指标。
